## **BLISS GVS PHARMA LTD.**



April 01, 2022

To

The Manager, Listing Department

National Stock Exchange of India Ltd.

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai-400 051

Symbol: BLISSGVS

To

The General Manager, Listing Department

**BSE Limited** 

Phiroze Jeejeebhoy Towers,

Dalal Street,

Mumbai-400 001

Scrip Code: 506197

Dear Sir/Madam,

Sub: Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 by Promoter of the Company

This is to inform you that, pursuant to the Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulation 2011, the Company has received disclosure from Dr. Vibha Gagan Sharma, Promoter cum Director of the Company with respect to acquisition of 3,50,000 shares of the company.

This is for your information and record.

Thanking you.

Yours Faithfully,

For Bliss GVS Pharma Limited

Aditi Bhatt

Company Secretary

Encl: a/a

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory:

Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

## March 31, 2022

To,	To,	To,
Corporate Relationship Dept.,	Listing Department,	Bliss GVS Pharma Limited
BSE Limited,	National Stock Exchange of	102, Hyde Park, Saki Vihar
Phiroze Jeejeebhoy Towers,	India Ltd.,	Road, Andheri (East). Mumbai
Dalal Street,	Exchange Plaza, C-1, Block G,	- 400072.
Mumbai-400001.	Bandra Kurla Complex,	
Scrip Code: <b>506197</b>	Bandra (E). Mumbai-400 051	
	Symbol: BLISSGVS	

## Subject: Disclosure pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Dear Sir/Madam,

Enclosed herewith the disclosure as required in terms of Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, as amended from time to time in respect of acquisition of 3,50,000 shares of Bliss GVS Pharma Limited by way of open market.

Kindly acknowledge receipt of the same.

Vebla n. Kamath

Thanking you.

Vibha Gagan Sharma

Promoter cum Director

Encl: a/a

## <u>Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011</u>

Name of the Target Company (TC)		Bliss GVS Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer		Acquirer – Dr. Vibha Gagan Sharma PAC – Mr. Narsimha Shibroor Kamath Mrs. Shruti Vishal Rao		
Whether the acquirer belongs to Promoter/Promoter group		Yes		
Name(s Listed	s) of the Stock Exchange(s) where the shares of TC are	The BSE Limited and National Stock Exchange of India Limited		
Details of the acquisition <del>/ disposal</del> as follows		Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
Bef	fore the disposal under consideration, holding of :		et.	24
a)	Shares carrying voting rights	15,00,000	1.45	NA
b)	Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)	Nil	Nil	Nil
b)	Voting rights (VR) otherwise than by shares	Nil	Nil	Nil
d)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the T C (specify holding in each category)	Nil	Nil	Nil
e)	Total (a+b+c+d)	15,00,000	1.45	NA
	Details of acquisition/sale			
a)	Shares carrying voting rights acquired/sold	3,50,000	0.34	NA
b)	VRs acquired /sold otherwise than by shares	Nil	Nil	Nil
c)	Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired/sold	Nil	Nil	Nil
c)	Shares encumbered / invoked/released by the acquirer	Nil	Nil	Nil
e)	Total (a+b+c+/-d)	3,50,000	0.34	NA

After the acquisition/sale, holding of:				
a) Shares carrying voting rights	18,50,000	1.79	NA	
b) Shares encumbered with the acquirer	Nil	Nil	Nil	
c) VRs otherwise than by shares	Nil	Nil	Nil	
d) Warrants/convertible securities/any other instrumen that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	1111	Nil	Nil	
e) Total (a+b+c+d)	18,50,000	1.79	NA	
Mode of acquisition /sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc)	Open market			
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	March 31, 2022			
Equity share capital / total voting capital of the TC before the said acquisition /-sale	Rs. 10,36,77,922			
Equity share capital/ total voting capital of the TC after the said acquisition /sale	Rs. 10,36,7	Rs. 10,36,77,922		
Total diluted share/voting capital of the TC after the said acquisition	NA			

<sup>(\*)</sup> Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

Vibla · n · Kaueath
Signature of the acquirer

Place: Mumbai

Date: 31.03.2022

\*\*\*\*\*

<sup>(\*\*)</sup> Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.